世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

EMEAの経口用固形動物薬市場-2031年までの産業動向と予測


EMEA Solid Oral Veterinary Exciepient Market - Industry Trends and Forecast to 2031

EMEAの動物用固形経口賦形剤市場は、2023年の187,632.69千米ドルから2031年には300,011.11千米ドルに達すると予測され、2024年から2031年の予測期間における年平均成長率は6.2％である。 市場区分 EMEA固形経... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年12月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		572 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

EMEAの動物用固形経口賦形剤市場は、2023年の187,632.69千米ドルから2031年には300,011.11千米ドルに達すると予測され、2024年から2031年の予測期間における年平均成長率は6.2％である。

市場区分
EMEA固形経口動物用添加剤市場：機能性別（結合剤、充填剤、希釈剤、増量剤、崩壊剤、滑沢剤、コーティング剤、香料、着色剤、緩衝剤、その他）、起源タイプ別（有機化学品、無機化学品）、剤形（錠剤、カプセル、その他）、動物（家畜、ペット）、用途（抗感染症薬、抗炎症薬、栄養補助食品、その他）、流通チャネル（直接入札、小売販売、その他）、国（ドイツ、フランス、イタリア、U.K.,スペイン, ロシア, オーストリア, オランダ, ハンガリー, ポーランド, スイス, トルコ, その他のEMEA, 南アフリカ, エジプト, サウジアラビア, イスラエル, アラブ首長国連邦, クウェート, その他の中東・アフリカ) - 2031年までの産業動向と予測
EMEAの固形経口動物用添加剤市場ダイナミクスの概要

促進要因
- ペット飼育率の上昇とペットの人間化
抑制要因

- 動物用添加物による副作用

機会

- 動物の健康とウェルネスのための栄養補助食品の採用増加

市場プレーヤー

EMEAの固形経口動物用賦形剤市場に参入している主要企業は以下の通り：
- JRS PHARMA
- BASF社
- アシュランド
- エボニック・インダストリーズAG
- カラーコン
- ロケット・フレール
- メルク KGaA
- ケリーグループ plc
- インターナショナル・フレーバー＆フレグランス社
- クロダ・インターナショナル
- ビオグランド
- デュ・ポイント
- メグルGmbH & Co.KG
- ペットフレーバーズLLC
- ファーマトランス - サナックAG
- セピック
- SPIファーマ
- DFEファーマ





ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET 84
1.4 MARKETS COVERED 87
2 MARKET SEGMENTATION 91
2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 CURRENCY AND PRICING 93
2.5 DBMR TRIPOD DATA VALIDATION MODEL 94
2.6 MULTIVARIATE MODELLING 97
2.7 TYPE LIFELINE CURVE 97
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 98
2.9 DBMR MARKET POSITION GRID 99
2.10 MARKET APPLICATION COVERAGE GRID 100
2.11 VENDOR SHARE ANALYSIS 101
2.12 SECONDARY SOURCES 102
2.13 ASSUMPTIONS 102
3 EXECUTIVE SUMMARY 103
4 PREMIUM INSIGHTS 105
4.1 PESTAL ANALYSIS 106
4.2 PORTERS 5 FORCES ANALYSIS 107
5 MARKET OVERVIEW 109
5.1 DRIVERS 111
5.1.1 RISING PET OWNERSHIP AND HUMANIZATION OF PETS 111
5.1.2 RISING PREVALENCE OF ZOONOTIC DISEASES 111
5.1.3 ADVANCEMENTS IN VETERINARY MEDICINES AND TECHNOLOGY 112
5.1.4 RISING FOCUS ON ANIMAL HEALTH AND WELL-BEING 112
5.2 RESTRAINTS 113
5.2.1 ADVERSE EFFECTS ASSOCIATED WITH VETERINARY EXCIPIENTS 113
5.2.2 STRICT REGULATIONS OVER APPROVAL OF THE VETERINARY EXCIPIENTS AND DRUGS 114
 
5.3 OPPORTUNITIES 115
5.3.1 TECHNOLOGICAL ADVANCEMENTS IN EXCIPIENT FORMULATIONS 115
5.3.2 INCREASING ADOPTION OF NUTRACEUTICALS FOR ANIMAL HEALTH AND WELLNESS 115
5.3.3 CUSTOMIZED FORMULATIONS FOR SPECIFIC ANIMAL SPECIES 116
5.3.4 GROWING CONSUMER PREFERENCE FOR NATURAL AND SUSTAINABLE PRODUCTS 116
5.4 CHALLENGES 117
5.4.1 FLUCTUATIONS IN GLOBAL ECONOMIC CONDITIONS 117
5.4.2 CONSUMER AWARENESS AND ACCEPTANCE 118
6 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY FUNCTIONALITY 119
6.1 OVERVIEW 120
6.2 BINDERS 123
6.3 FILLERS AND DILUENTS 125
6.4 BULKING AGENT 127
6.5 DISINTEGRANTS 128
6.6 LUBRICANTS 130
6.7 COATING AGENT 131
6.8 FLAVORING AGENT 133
6.9 COLURANTS 136
6.10 BUFFERING AGENT 138
6.11 OTHERS 139
7 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY ORIGIN TYPE 140
7.1 OVERVIEW 141
7.2 ORGANIC CHEMICALS 144
7.2.1 CELLULOSE 144
7.2.1.1 MICROCRYSTALLINE CELLULOSE 145
7.2.1.2 CELLULOSE ETHERS 145
7.2.1.3 CELLULOSE ESTERS 145
7.2.1.4 CMC AND CROSCARMELLOSE SODIUM 145
7.2.2 STARCH 146
7.2.2.1 MODIFIED STARCH 146
7.2.2.2 DRIED STARCH 146
7.2.2.3 CONVERTED STARCH 146
7.2.3 CARBOHYDRATES 147
7.2.3.1 SUGAR 147
7.2.3.2 ACTUAL SUGAR 147
7.2.3.3 SUGAR ALCOHOL 147
7.2.3.4 ARTIFICIAL SWEETENERS 147
7.2.3.5 OTHERS 147
7.2.4 OTHERS 148
7.3 INORGANIC CHEMICALS 148
7.3.1 CALCIUM CARBONATE 148
7.3.2 CALCIUM PHOSPHATE 148
7.3.3 HALITES 148
7.3.4 CALCIUM SULPHATE 148
7.3.5 METALLIC OXIDES 149
7.3.6 OTHERS 149
8 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY FORMULATION 150
8.1 OVERVIEW 151
8.2 TABLETS 154
8.3 CAPSULE 154
8.4 OTHERS 154
9 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY ANIMAL 155
9.1 OVERVIEW 156
9.2 FARM ANIMAL 159
9.3 PET ANIMAL 159
10 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY APPLICATION 160
10.1 OVERVIEW 161
10.2 ANTI-INFECTIVES 164
10.3 ANTI-INFLAMMATORY DRUGS 164
10.4 NUTRITIONAL SUPPLEMENTS 164
10.5 OTHERS 164
11 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL 165
11.1 OVERVIEW 166
11.2 DIRECT TENDER 169
11.3 RETAIL SALES 169
11.4 OTHERS 169
 
12 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET BY REGION 170
12.1 EUROPE 171
12.1.1 GERMANY 187
12.1.2 FRANCE 205
12.1.3 U.K. 224
12.1.4 ITALY 244
12.1.5 RUSSIA 263
12.1.6 SPAIN 282
12.1.7 TURKEY 302
12.1.8 BELGIUM 322
12.1.9 NETHERLANDS 343
12.1.10 SWITZERLAND 364
12.1.11 REST OF EUROPE 385
12.2 MIDDLE EAST AND AFRICA 386
12.2.1 SOUTH AFRICA 401
12.2.2 SAUDI ARABIA 419
12.2.3 U.A.E. 437
12.2.4 ALGERIA 455
12.2.5 OMAN 473
12.2.6 KUWAIT 491
12.2.7 REST OF MIDDLE EAST AND AFRICA 509
12.3 PAKISTAN 510
13 EUROPE SOLID ORAL VETERINARY EXCIPIENTS MARKET: COMPANY LANDSCAPE 528
13.1 COMPANY SHARE ANALYSIS: EUROPE 528
14 MIDDLE EAST AND AFRICA SOLID ORAL VETERINARY EXCIPIENTS MARKET: COMPANY LANDSCAPE 529
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 529
15 SWOT ANALYSIS 530
16 COMPANY PROFILES 531
16.1 JRS PHARMA 531
16.1.1 COMPANY SNAPSHOT 531
16.1.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 531
16.1.3 PRODUCT PORTFOLIO 532
16.1.4 RECENT DEVELOPMENTS 532

 
16.2 BASF CORPORATION 533
16.2.1 COMPANY SNAPSHOT 533
16.2.2 REVENUE ANALYSIS 533
16.2.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 534
16.2.4 PRODUCT PORTFOLIO 534
16.2.5 RECENT DEVELOPMENT 534
16.3 ASHLAND 535
16.3.1 COMPANY SNAPSHOT 535
16.3.2 REVENUE ANALYSIS 535
16.3.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 536
16.3.4 PRODUCT PORTFOLIO 536
16.3.5 RECENT DEVELOPMENTS 536
16.4 EVONIK INDUSTRIES AG 537
16.4.1 COMPANY SNAPSHOT 537
16.4.2 REVENUE ANALYSIS 537
16.4.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 538
16.4.4 PRODUCT PORTFOLIO 538
16.4.5 RECENT DEVELOPMENT 539
16.5 COLORCON 540
16.5.1 COMPANY SNAPSHOT 540
16.5.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 540
16.5.3 PRODUCT PORTFOLIO 540
16.5.4 RECENT DEVELOPMENTS 541
16.6 BIOGRUND GMBH 542
16.6.1 COMPANY SNAPSHOT 542
16.6.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 542
16.6.3 PRODUCT PORTFOLIO 542
16.6.4 RECENT DEVELOPMENTS 543
16.7 CRODA INTERNATIONAL PLC 544
16.7.1 COMPANY SNAPSHOT 544
16.7.2 REVENUE ANALYSIS 544
16.7.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 545
16.7.4 PRODUCT PORTFOLIO 545
16.7.5 RECENT DEVELOPMENT 545
16.8 DFE PHARMA 546
16.8.1 COMPANY SNAPSHOT 546
16.8.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 546
16.8.3 PRODUCT PORTFOLIO 546
16.8.4 RECENT DEVELOPMENT 547
 
16.9 DUPONT 548
16.9.1 COMPANY SNAPSHOT 548
16.9.2 REVENUE ANALYSIS 548
16.9.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 549
16.9.4 PRODUCT PORTFOLIO 549
16.9.5 RECENT DEVELOPMENTS 549
16.10 INTERNATIONAL FLAVORS & FRAGRANCES INC 550
16.10.1 COMPANY SNAPSHOT 550
16.10.2 REVENUE ANALYSIS 550
16.10.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 551
16.10.4 PRODUCT PORTFOLIO 551
16.10.5 RECENT DEVELOPMENTS 551
16.11 KERRY GROUP PLC 552
16.11.1 COMPANY SNAPSHOT 552
16.11.2 REVENUE ANALYSIS 552
16.11.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 553
16.11.4 PRODUCT PORTFOLIO 553
16.11.5 RECENT DEVELOPMENTS 554
16.12 MEGGLE GMBH & CO. KG 555
16.12.1 COMPANY SNAPSHOT 555
16.12.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 555
16.12.3 PRODUCT PORTFOLIO 555
16.12.4 RECENT DEVELOPMENT 556
16.13 MERCK KGAA 557
16.13.1 COMPANY SNAPSHOT 557
16.13.2 REVENUE ANALYSIS 557
16.13.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 558
16.13.4 PRODUCT PORTFOLIO 558
16.13.5 RECENT DEVELOPMENTS 559
16.14 PET FLAVORS LLC 560
16.14.1 COMPANY SNAPSHOT 560
16.14.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 560
16.14.3 PRODUCT PORTFOLIO 560
16.14.4 RECENT DEVELOPMENTS 560
16.15 PHARMATRANS - SANAQ AG 561
16.15.1 COMPANY SNAPSHOT 561
16.15.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 561
16.15.3 PRODUCT PORTFOLIO 561
16.15.4 RECENT DEVELOPMENTS 562
 
16.16 ROQUETTE FRÈRES 563
16.16.1 COMPANY SNAPSHOT 563
16.16.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 563
16.16.3 PRODUCT PORTFOLIO 563
16.16.4 RECENT DEVELOPMENTS 564
16.17 SEPPIC 565
16.17.1 COMPANY SNAPSHOT 565
16.17.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 565
16.17.3 PRODUCT PORTFOLIO 565
16.17.4 RECENT DEVELOPMENT 566
16.18 SPI PHARMA 567
16.18.1 COMPANY SNAPSHOT 567
16.18.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 567
16.18.3 PRODUCT PORTFOLIO 567
16.18.4 RECENT DEVELOPMENT 567
17 QUESTIONNAIRE 568
18 RELATED REPORTS 572

　

ページTOPに戻る


　

Summary

The EMEA solid oral veterinary excipients market is expected to reach USD 300,011.11 thousand by 2031 from USD 187,632.69 thousand in 2023, growing with a CAGR of 6.2% in the forecast period of 2024 to 2031.

Market Segmentation
EMEA Solid Oral Veterinary Excipients Market, By Functionality (Binders, Fillers and Diluents, Bulking Agents, Disintegrants, Lubricants, Coating Agents, Flavouring Agents, Colorants, Buffering Agents, and Others), Origin Type (Organic Chemicals and Inorganic Chemicals), Formulation (Tablets, Capsule, and Others), Animal (Farm Animal and Pet Animal), Application (Anti-Infectives, Anti-Inflammatory Drugs, Nutritional Supplements, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Rest of EMEA, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa) – Industry Trends and Forecast to 2031
Overview of EMEA Solid Oral Veterinary Excipients Market Dynamics

Driver
• Rising pet ownership and humanization of pets
Restraint

• Adverse effects associated with veterinary excipients

Opportunity

• Increasing adoption of nutraceuticals for animal health and wellness

Market Players

Some of the key players operating in the EMEA solid oral veterinary excipients market are:
• JRS PHARMA
• BASF Corporation
• Ashland
• Evonik Industries AG
• Colorcon
• Roquette Frères.
• Merck KGaA
• Kerry Group plc
• International Flavors & Fragrances Inc.
• Croda International Plc
• Biogrund Gmbh
• Du Point
• Meggle GmbH & Co.KG
• Pet Flavours LLC
• Pharmatrans - Sanaq AG
• SEPPIC
• SPI Pharma
• DFE Pharma





ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET 84
1.4 MARKETS COVERED 87
2 MARKET SEGMENTATION 91
2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 CURRENCY AND PRICING 93
2.5 DBMR TRIPOD DATA VALIDATION MODEL 94
2.6 MULTIVARIATE MODELLING 97
2.7 TYPE LIFELINE CURVE 97
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 98
2.9 DBMR MARKET POSITION GRID 99
2.10 MARKET APPLICATION COVERAGE GRID 100
2.11 VENDOR SHARE ANALYSIS 101
2.12 SECONDARY SOURCES 102
2.13 ASSUMPTIONS 102
3 EXECUTIVE SUMMARY 103
4 PREMIUM INSIGHTS 105
4.1 PESTAL ANALYSIS 106
4.2 PORTERS 5 FORCES ANALYSIS 107
5 MARKET OVERVIEW 109
5.1 DRIVERS 111
5.1.1 RISING PET OWNERSHIP AND HUMANIZATION OF PETS 111
5.1.2 RISING PREVALENCE OF ZOONOTIC DISEASES 111
5.1.3 ADVANCEMENTS IN VETERINARY MEDICINES AND TECHNOLOGY 112
5.1.4 RISING FOCUS ON ANIMAL HEALTH AND WELL-BEING 112
5.2 RESTRAINTS 113
5.2.1 ADVERSE EFFECTS ASSOCIATED WITH VETERINARY EXCIPIENTS 113
5.2.2 STRICT REGULATIONS OVER APPROVAL OF THE VETERINARY EXCIPIENTS AND DRUGS 114
 
5.3 OPPORTUNITIES 115
5.3.1 TECHNOLOGICAL ADVANCEMENTS IN EXCIPIENT FORMULATIONS 115
5.3.2 INCREASING ADOPTION OF NUTRACEUTICALS FOR ANIMAL HEALTH AND WELLNESS 115
5.3.3 CUSTOMIZED FORMULATIONS FOR SPECIFIC ANIMAL SPECIES 116
5.3.4 GROWING CONSUMER PREFERENCE FOR NATURAL AND SUSTAINABLE PRODUCTS 116
5.4 CHALLENGES 117
5.4.1 FLUCTUATIONS IN GLOBAL ECONOMIC CONDITIONS 117
5.4.2 CONSUMER AWARENESS AND ACCEPTANCE 118
6 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY FUNCTIONALITY 119
6.1 OVERVIEW 120
6.2 BINDERS 123
6.3 FILLERS AND DILUENTS 125
6.4 BULKING AGENT 127
6.5 DISINTEGRANTS 128
6.6 LUBRICANTS 130
6.7 COATING AGENT 131
6.8 FLAVORING AGENT 133
6.9 COLURANTS 136
6.10 BUFFERING AGENT 138
6.11 OTHERS 139
7 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY ORIGIN TYPE 140
7.1 OVERVIEW 141
7.2 ORGANIC CHEMICALS 144
7.2.1 CELLULOSE 144
7.2.1.1 MICROCRYSTALLINE CELLULOSE 145
7.2.1.2 CELLULOSE ETHERS 145
7.2.1.3 CELLULOSE ESTERS 145
7.2.1.4 CMC AND CROSCARMELLOSE SODIUM 145
7.2.2 STARCH 146
7.2.2.1 MODIFIED STARCH 146
7.2.2.2 DRIED STARCH 146
7.2.2.3 CONVERTED STARCH 146
7.2.3 CARBOHYDRATES 147
7.2.3.1 SUGAR 147
7.2.3.2 ACTUAL SUGAR 147
7.2.3.3 SUGAR ALCOHOL 147
7.2.3.4 ARTIFICIAL SWEETENERS 147
7.2.3.5 OTHERS 147
7.2.4 OTHERS 148
7.3 INORGANIC CHEMICALS 148
7.3.1 CALCIUM CARBONATE 148
7.3.2 CALCIUM PHOSPHATE 148
7.3.3 HALITES 148
7.3.4 CALCIUM SULPHATE 148
7.3.5 METALLIC OXIDES 149
7.3.6 OTHERS 149
8 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY FORMULATION 150
8.1 OVERVIEW 151
8.2 TABLETS 154
8.3 CAPSULE 154
8.4 OTHERS 154
9 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY ANIMAL 155
9.1 OVERVIEW 156
9.2 FARM ANIMAL 159
9.3 PET ANIMAL 159
10 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY APPLICATION 160
10.1 OVERVIEW 161
10.2 ANTI-INFECTIVES 164
10.3 ANTI-INFLAMMATORY DRUGS 164
10.4 NUTRITIONAL SUPPLEMENTS 164
10.5 OTHERS 164
11 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL 165
11.1 OVERVIEW 166
11.2 DIRECT TENDER 169
11.3 RETAIL SALES 169
11.4 OTHERS 169
 
12 EMEA SOLID ORAL VETERINARY EXCIPIENTS MARKET BY REGION 170
12.1 EUROPE 171
12.1.1 GERMANY 187
12.1.2 FRANCE 205
12.1.3 U.K. 224
12.1.4 ITALY 244
12.1.5 RUSSIA 263
12.1.6 SPAIN 282
12.1.7 TURKEY 302
12.1.8 BELGIUM 322
12.1.9 NETHERLANDS 343
12.1.10 SWITZERLAND 364
12.1.11 REST OF EUROPE 385
12.2 MIDDLE EAST AND AFRICA 386
12.2.1 SOUTH AFRICA 401
12.2.2 SAUDI ARABIA 419
12.2.3 U.A.E. 437
12.2.4 ALGERIA 455
12.2.5 OMAN 473
12.2.6 KUWAIT 491
12.2.7 REST OF MIDDLE EAST AND AFRICA 509
12.3 PAKISTAN 510
13 EUROPE SOLID ORAL VETERINARY EXCIPIENTS MARKET: COMPANY LANDSCAPE 528
13.1 COMPANY SHARE ANALYSIS: EUROPE 528
14 MIDDLE EAST AND AFRICA SOLID ORAL VETERINARY EXCIPIENTS MARKET: COMPANY LANDSCAPE 529
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 529
15 SWOT ANALYSIS 530
16 COMPANY PROFILES 531
16.1 JRS PHARMA 531
16.1.1 COMPANY SNAPSHOT 531
16.1.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 531
16.1.3 PRODUCT PORTFOLIO 532
16.1.4 RECENT DEVELOPMENTS 532

 
16.2 BASF CORPORATION 533
16.2.1 COMPANY SNAPSHOT 533
16.2.2 REVENUE ANALYSIS 533
16.2.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 534
16.2.4 PRODUCT PORTFOLIO 534
16.2.5 RECENT DEVELOPMENT 534
16.3 ASHLAND 535
16.3.1 COMPANY SNAPSHOT 535
16.3.2 REVENUE ANALYSIS 535
16.3.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 536
16.3.4 PRODUCT PORTFOLIO 536
16.3.5 RECENT DEVELOPMENTS 536
16.4 EVONIK INDUSTRIES AG 537
16.4.1 COMPANY SNAPSHOT 537
16.4.2 REVENUE ANALYSIS 537
16.4.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 538
16.4.4 PRODUCT PORTFOLIO 538
16.4.5 RECENT DEVELOPMENT 539
16.5 COLORCON 540
16.5.1 COMPANY SNAPSHOT 540
16.5.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 540
16.5.3 PRODUCT PORTFOLIO 540
16.5.4 RECENT DEVELOPMENTS 541
16.6 BIOGRUND GMBH 542
16.6.1 COMPANY SNAPSHOT 542
16.6.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 542
16.6.3 PRODUCT PORTFOLIO 542
16.6.4 RECENT DEVELOPMENTS 543
16.7 CRODA INTERNATIONAL PLC 544
16.7.1 COMPANY SNAPSHOT 544
16.7.2 REVENUE ANALYSIS 544
16.7.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 545
16.7.4 PRODUCT PORTFOLIO 545
16.7.5 RECENT DEVELOPMENT 545
16.8 DFE PHARMA 546
16.8.1 COMPANY SNAPSHOT 546
16.8.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 546
16.8.3 PRODUCT PORTFOLIO 546
16.8.4 RECENT DEVELOPMENT 547
 
16.9 DUPONT 548
16.9.1 COMPANY SNAPSHOT 548
16.9.2 REVENUE ANALYSIS 548
16.9.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 549
16.9.4 PRODUCT PORTFOLIO 549
16.9.5 RECENT DEVELOPMENTS 549
16.10 INTERNATIONAL FLAVORS & FRAGRANCES INC 550
16.10.1 COMPANY SNAPSHOT 550
16.10.2 REVENUE ANALYSIS 550
16.10.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 551
16.10.4 PRODUCT PORTFOLIO 551
16.10.5 RECENT DEVELOPMENTS 551
16.11 KERRY GROUP PLC 552
16.11.1 COMPANY SNAPSHOT 552
16.11.2 REVENUE ANALYSIS 552
16.11.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 553
16.11.4 PRODUCT PORTFOLIO 553
16.11.5 RECENT DEVELOPMENTS 554
16.12 MEGGLE GMBH & CO. KG 555
16.12.1 COMPANY SNAPSHOT 555
16.12.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 555
16.12.3 PRODUCT PORTFOLIO 555
16.12.4 RECENT DEVELOPMENT 556
16.13 MERCK KGAA 557
16.13.1 COMPANY SNAPSHOT 557
16.13.2 REVENUE ANALYSIS 557
16.13.3 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 558
16.13.4 PRODUCT PORTFOLIO 558
16.13.5 RECENT DEVELOPMENTS 559
16.14 PET FLAVORS LLC 560
16.14.1 COMPANY SNAPSHOT 560
16.14.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 560
16.14.3 PRODUCT PORTFOLIO 560
16.14.4 RECENT DEVELOPMENTS 560
16.15 PHARMATRANS - SANAQ AG 561
16.15.1 COMPANY SNAPSHOT 561
16.15.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 561
16.15.3 PRODUCT PORTFOLIO 561
16.15.4 RECENT DEVELOPMENTS 562
 
16.16 ROQUETTE FRÈRES 563
16.16.1 COMPANY SNAPSHOT 563
16.16.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 563
16.16.3 PRODUCT PORTFOLIO 563
16.16.4 RECENT DEVELOPMENTS 564
16.17 SEPPIC 565
16.17.1 COMPANY SNAPSHOT 565
16.17.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 565
16.17.3 PRODUCT PORTFOLIO 565
16.17.4 RECENT DEVELOPMENT 566
16.18 SPI PHARMA 567
16.18.1 COMPANY SNAPSHOT 567
16.18.2 REVENUE AND VOLUME ANALYSIS, BY FUNCTIONALITY 567
16.18.3 PRODUCT PORTFOLIO 567
16.18.4 RECENT DEVELOPMENT 567
17 QUESTIONNAIRE 568
18 RELATED REPORTS 572

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

Data Bridge Market Research社の医薬分野での最新刊レポート

本レポートと同じKEY WORD（veterinary）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15　10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.